CureVac draws conclusions from the disappointing study results of its Covid-19 vaccine.
The Tübingen biotech company gives up its first production partnerships for the manufacture of the vaccine.
The contracts with Wacker and Celonic had been terminated, announced CureVac on Tuesday.
The contracts with Rentschler Biopharma and Novartis, however, remained in place.
CureVac attributed this to lower demand for its vaccine, which only showed 48 percent overall effectiveness in the crucial clinical trial.
Whether the vaccine will ever be approved is completely open. It is currently being examined by the European Medicines Agency (EMA).